Lepu Biopharma’s MRG003 Gains FDA Breakthrough Status

Lepu Biopharma Co. Ltd. Class H (HK:2157) has released an update.

Lepu Biopharma Co. Ltd. has announced that its drug candidate MRG003 received the FDA’s Breakthrough Therapy Designation for treating recurrent or metastatic nasopharyngeal cancer, marking significant progress in the drug’s development and potential market opportunities. The designation will expedite MRG003’s development process and review, highlighting the FDA’s acknowledgment of its promising clinical data. This achievement underscores the company’s strides towards internationalization and its commitment to providing new treatment options.

For further insights into HK:2157 stock, check out TipRanks’ Stock Analysis page.